Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > COLUMN
COLUMN
- Maurer's Healthcare Insight (75)
May 29, 2006
- Maurer's Healthcare Insight (74)
April 10, 2006
- Maurer's Healthcare Insight (73)
March 13, 2006
- Maurer's Healthcare Insight (71)
December 19, 2005
- Maurer's Healthcare Insight (70)
November 28, 2005
- Maurer's Healthcare Insight(69)
November 14, 2005
- Maurer's Healthcare Insight (68)
October 17, 2005
- Maurer's Healthcare Insight (67)
September 26, 2005
- Maurer's Healthcare Insight (66)
August 8, 2005
- Maurer's Healthcare Insight (65)
July 11, 2005
- Maurer's Healthcare Insight (64)
June 13, 2005
- Maurer's Healthcare Insight (63)
May 30, 2005
- Maurer's Healthcare Insight (62)
April 25, 2005
- Maurer's Healthcare Insight (61)
March 28, 2005
- Maurer's Healthcare Insight (60)
March 14, 2005
- Maurer's Healthcare Insight (59)
December 6, 2004
- Maurer's Healthcare Insight (58)
November 8, 2004
- Maurer's Healthcare Insight (57)
October 11, 2004
- Maurer's Healthcare Insight (56)
September 13, 2004
- Maurer's Healthcare Insight (55)
July 26, 2004
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…